Clinical trial
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT01670877 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 11, 2012
- Completion date
- March 11, 2021
- Enrollment
- 56 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.